Nurix Therapeutics
Quarterly Financials
| Values in thousands | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 |
|---|---|---|---|---|
Revenue | $44,056 | $18,453 | $13,284 | $12,588 |
Gross Profit | 44,056 | 18,453 | 13,284 | 4,139 |
EBITDA | -48,322 | -58,736 | -60,354 | -50,465 |
EBIT | -53,419 | -62,864 | -64,657 | -54,611 |
Net Income | -43,464 | -56,351 | -58,549 | -48,956 |
Net Change In Cash | 44,056 | 18,453 | 13,284 | 12,588 |
Free Cash Flow | -65,836 | -64,572 | -50,856 | -44,524 |
Cash | 84,260 | 75,916 | 109,997 | 99,044 |
Basic Shares | 83,882 | 83,560 | 78,410 | 72,779 |
Annual Financials
| Values in thousands | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 |
|---|---|---|---|---|
Revenue | $54,549 | $76,987 | $38,627 | $29,750 |
Gross Profit | 38,121 | 63,333 | 38,627 | 29,750 |
EBITDA | -196,599 | -141,409 | -173,059 | -111,804 |
EBIT | -213,027 | -155,063 | -183,867 | -117,886 |
Net Income | -193,569 | -143,948 | -166,045 | -117,194 |
Net Change In Cash | 54,549 | 76,987 | 38,627 | 29,750 |
Cost of Revenue | -15,417 | -38,734 | ||
Free Cash Flow | -181,857 | -89,766 | -172,051 | -90,026 |
Cash | 109,997 | 54,627 | 64,474 | 80,506 |
Basic Shares | 67,120 | 54,337 | 48,607 | 42,895 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-11-30 | $0 |
2025-08-31 | -$1.03 |
2025-05-31 | -$0.52 |
2025-02-28 | -$0.67 |
